NZCC to issue statement on Zoetis's proposed Neogen unit deal

The New Zealand Commerce Commission (NZCC) is expected to issue a formal statement regarding Zoetis Inc.’s proposed acquisition of Neogen Corporation’s animal genomics business. The deal, valued at $160 million, is part of Zoetis’ broader strategy to enhance its Precision Animal Health portfolio by integrating Neogen’s global genomics capabilities. The acquisition is subject to regulatory approvals and is anticipated to close in the second half of 2026.

Neogen’s genomics business operates in over 120 countries and provides advanced genetic testing and data-driven solutions for livestock and companion animals. Zoetis has emphasized that the acquisition aligns with its mission to improve animal health and sustainability through innovation and technology.

The NZCC’s review will likely assess the transaction’s compliance with competition laws and its potential impact on market dynamics in New Zealand and beyond. Zoetis has committed to a seamless integration of the acquired business, ensuring continuity for employees and customers. The company also highlighted that the acquisition supports its long-term growth strategy and strengthens its position in the global animal health market.

As the NZCC prepares its statement, stakeholders will be watching closely for any conditions or requirements that may be imposed on the transaction. The outcome could influence the broader regulatory landscape for cross-border acquisitions in the animal health sector.